Linked Life Data

10438477

Source:http://linkedlifedata.com/resource/pubmed/id/10438477

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10438477rdf:typepubmed:Citationlld:pubmed
pubmed-article:10438477lifeskim:mentionsumls-concept:C0332307lld:lifeskim
pubmed-article:10438477lifeskim:mentionsumls-concept:C0021753lld:lifeskim
pubmed-article:10438477lifeskim:mentionsumls-concept:C0026844lld:lifeskim
pubmed-article:10438477lifeskim:mentionsumls-concept:C1135918lld:lifeskim
pubmed-article:10438477lifeskim:mentionsumls-concept:C0752063lld:lifeskim
pubmed-article:10438477lifeskim:mentionsumls-concept:C0521447lld:lifeskim
pubmed-article:10438477lifeskim:mentionsumls-concept:C0017337lld:lifeskim
pubmed-article:10438477lifeskim:mentionsumls-concept:C0031672lld:lifeskim
pubmed-article:10438477lifeskim:mentionsumls-concept:C1521761lld:lifeskim
pubmed-article:10438477lifeskim:mentionsumls-concept:C1522240lld:lifeskim
pubmed-article:10438477lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:10438477pubmed:issue33lld:pubmed
pubmed-article:10438477pubmed:dateCreated1999-9-1lld:pubmed
pubmed-article:10438477pubmed:abstractTextType II-secreted phospholipase A(2) (type II-sPLA(2)) is expressed in smooth muscle cells during atherosclerosis or in response to interleukin-1beta. The present study shows that the induction of type II-sPLA(2) gene by interleukin-1beta requires activation of the NFkappaB pathway and cytosolic PLA(2)/PPARgamma pathway, which are both necessary to achieve the transcriptional process. Interleukin-1beta induced type II-sPLA(2) gene dose- and time-dependently and increased the binding of NFkappaB to a specific site of type II-sPLA(2) promoter. This effect was abolished by proteinase inhibitors that block the proteasome machinery and NFkappaB nuclear translocation. Type II-sPLA(2) induction was also obtained by free arachidonic acid and was blocked by either AACOCF(3), a specific cytosolic-PLA(2) inhibitor, PD98059, a mitogen-activated protein kinase kinase inhibitor which prevents cytosolic PLA(2) activation, or nordihydroguaiaretic acid, a lipoxygenase inhibitor, but not by the cyclooxygenase inhibitor indomethacin, suggesting a role for a lipoxygenase product. Type II-sPLA(2) induction was obtained after treatment of the cells by 15-deoxy-Delta(12,14)-dehydroprostaglandin J(2), carbaprostacyclin, and 9-hydroxyoctadecadienoic acid, which are ligands of peroxisome proliferator-activated receptor (PPAR) gamma, whereas PPARalpha ligands were ineffective. Interleukin-1beta as well as PPARgamma-ligands stimulated the activity of a reporter gene containing PPARgamma-binding sites in its promoter. Binding of both NFkappaB and PPARgamma to their promoter is required to stimulate the transcriptional process since inhibitors of each class block interleukin-1beta-induced type II-sPLA(2) gene activation. We therefore suggest that NFkappaB and PPARgamma cooperate at the enhanceosome-coactivator level to turn on transcription of the proinflammatory type II-sPLA(2) gene.lld:pubmed
pubmed-article:10438477pubmed:languageenglld:pubmed
pubmed-article:10438477pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10438477pubmed:citationSubsetIMlld:pubmed
pubmed-article:10438477pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10438477pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10438477pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10438477pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10438477pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10438477pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10438477pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10438477pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10438477pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10438477pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10438477pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10438477pubmed:statusMEDLINElld:pubmed
pubmed-article:10438477pubmed:monthAuglld:pubmed
pubmed-article:10438477pubmed:issn0021-9258lld:pubmed
pubmed-article:10438477pubmed:authorpubmed-author:BéréziatGGlld:pubmed
pubmed-article:10438477pubmed:authorpubmed-author:KoumanovKKlld:pubmed
pubmed-article:10438477pubmed:authorpubmed-author:CouturierCClld:pubmed
pubmed-article:10438477pubmed:authorpubmed-author:BrouilletAAlld:pubmed
pubmed-article:10438477pubmed:authorpubmed-author:CouriaudCClld:pubmed
pubmed-article:10438477pubmed:authorpubmed-author:AndréaniMMlld:pubmed
pubmed-article:10438477pubmed:issnTypePrintlld:pubmed
pubmed-article:10438477pubmed:day13lld:pubmed
pubmed-article:10438477pubmed:volume274lld:pubmed
pubmed-article:10438477pubmed:ownerNLMlld:pubmed
pubmed-article:10438477pubmed:authorsCompleteYlld:pubmed
pubmed-article:10438477pubmed:pagination23085-93lld:pubmed
pubmed-article:10438477pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:10438477pubmed:meshHeadingpubmed-meshheading:10438477...lld:pubmed
pubmed-article:10438477pubmed:meshHeadingpubmed-meshheading:10438477...lld:pubmed
pubmed-article:10438477pubmed:meshHeadingpubmed-meshheading:10438477...lld:pubmed
pubmed-article:10438477pubmed:meshHeadingpubmed-meshheading:10438477...lld:pubmed
pubmed-article:10438477pubmed:meshHeadingpubmed-meshheading:10438477...lld:pubmed
pubmed-article:10438477pubmed:meshHeadingpubmed-meshheading:10438477...lld:pubmed
pubmed-article:10438477pubmed:meshHeadingpubmed-meshheading:10438477...lld:pubmed
pubmed-article:10438477pubmed:meshHeadingpubmed-meshheading:10438477...lld:pubmed
pubmed-article:10438477pubmed:meshHeadingpubmed-meshheading:10438477...lld:pubmed
pubmed-article:10438477pubmed:meshHeadingpubmed-meshheading:10438477...lld:pubmed
pubmed-article:10438477pubmed:meshHeadingpubmed-meshheading:10438477...lld:pubmed
pubmed-article:10438477pubmed:meshHeadingpubmed-meshheading:10438477...lld:pubmed
pubmed-article:10438477pubmed:meshHeadingpubmed-meshheading:10438477...lld:pubmed
pubmed-article:10438477pubmed:meshHeadingpubmed-meshheading:10438477...lld:pubmed
pubmed-article:10438477pubmed:meshHeadingpubmed-meshheading:10438477...lld:pubmed
pubmed-article:10438477pubmed:meshHeadingpubmed-meshheading:10438477...lld:pubmed
pubmed-article:10438477pubmed:meshHeadingpubmed-meshheading:10438477...lld:pubmed
pubmed-article:10438477pubmed:meshHeadingpubmed-meshheading:10438477...lld:pubmed
pubmed-article:10438477pubmed:meshHeadingpubmed-meshheading:10438477...lld:pubmed
pubmed-article:10438477pubmed:meshHeadingpubmed-meshheading:10438477...lld:pubmed
pubmed-article:10438477pubmed:meshHeadingpubmed-meshheading:10438477...lld:pubmed
pubmed-article:10438477pubmed:meshHeadingpubmed-meshheading:10438477...lld:pubmed
pubmed-article:10438477pubmed:year1999lld:pubmed
pubmed-article:10438477pubmed:articleTitleInterleukin 1beta induces type II-secreted phospholipase A(2) gene in vascular smooth muscle cells by a nuclear factor kappaB and peroxisome proliferator-activated receptor-mediated process.lld:pubmed
pubmed-article:10438477pubmed:affiliationUnité Propre de Recherche de l'Université Pierre et Marie Curie, Associée au CNRS, ESA7079, 7 quai St. Bernard, 75252 Paris, Cedex 5, France.lld:pubmed
pubmed-article:10438477pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10438477pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10438477lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10438477lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10438477lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10438477lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10438477lld:pubmed